Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

G. Cartron · SciRah

Researcher profile · Semantic Scholar

G. Cartron

Share profile

G. Cartron — researcher profile on SciRah

h-index: 61
Works: 490
Citations: 17K

Most-cited papers

Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study
Franck Morschhauser, Saurabh Dahiya, M. Palomba, A. Martin Garcia-Sancho +29 more
2024Nature Medicine147 citations Open access
Semantic Scholar
Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial
R. Houot, E. Bachy, G. Cartron, F. Gros +25 more
2023Nature Medicine102 citations Open access
Semantic Scholar
Nonrelapse mortality after CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry
J. Lemoine, E. Bachy, G. Cartron, D. Beauvais +20 more
2023Blood Advances74 citations Open access
Semantic Scholar
Efficacy of CAR T-Cell Therapy is Not Impaired by Previous Bispecific Antibody Treatment in Large B-Cell Lymphoma.
Gilles Crochet, G. Iacoboni, Audrey Couturier, E. Bachy +22 more
2024Blood61 citations Open access
Semantic Scholar
Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study
W. Townsend, W. Hiddemann, C. Buske, G. Cartron +15 more
2023HemaSphere60 citations Open access
Semantic Scholar
Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphoma
P. Sesques, A. Kirkwood, Mi Kwon, K. Rejeski +34 more
2024Journal of Hematology & Oncology40 citations Open access
Semantic Scholar
Arginine metabolism regulates human erythroid differentiation through hypusination of eIF5A.
P. González-Menéndez, I. Phadke, M. Olive, Axel Joly +29 more
2023Blood38 citations Open access
Semantic Scholar
Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study.
J. Dupuis, E. Bachy, Franck Morschhauser, G. Cartron +24 more
2024The Lancet Haematology35 citations Open access
Semantic Scholar
Fixed-Duration Glofitamab Monotherapy Continues to Demonstrate Durable Responses in Patients with Relapsed or Refractory Large B-Cell Lymphoma: 3-Year Follow-up from a Pivotal Phase II Study
M. Dickinson, Carmelo Carlo-Stella, F. Morschhauser, E. Bachy +16 more
2024Blood31 citations
Semantic Scholar
Glofitamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma: Extended Follow-Up from a Pivotal Phase II Study and Subgroup Analyses in Patients with Prior Chimeric Antigen Receptor T-Cell Therapy and by Baseline Total Metabolic Tumor Volume
Martin Hutchings, Carmelo Carlo-Stella, F. Morschhauser, L. Falchi +16 more
2023Blood31 citations Open access
Semantic Scholar
Comparative analysis of CAR T-cell therapy access for DLBCL patients: associated challenges and solutions in the four largest EU countries
M. Canales Albendea, P. Canonico, G. Cartron, B. Deiters +6 more
2023Frontiers in Medicine29 citations Open access
Semantic Scholar
Transfusion needs after CAR T-cell therapy for large B-cell lymphoma: predictive factors and outcome (a DESCAR-T study)
S. Vic, J. Thibert, E. Bachy, G. Cartron +18 more
2024Blood Advances28 citations Open access
Semantic Scholar
Englumafusp Alfa (CD19-4-1BBL) Combined with Glofitamab Is Safe and Efficacious in Patients with r/r B-NHL: Extended Follow up Analysis of the Dose-Escalation Part of Phase 1 Trial BP41072
Martin Hutchings, M. Dickinson, G. Gritti, Carmelo Carlo-Stella +23 more
2024Blood23 citations
Semantic Scholar
Frontal Intermittent Rhythmic Delta Activity Is a Useful Diagnostic Tool of Neurotoxicity After CAR T-Cell Infusion
Sophie Huby, P. Gélisse, J. Tudesq, P. Labauge +9 more
2023Neurology: Neuroimmunology & Neuroinflammation18 citations Open access
Semantic Scholar
Outcomes of patients with relapsed or refractory primary mediastinal B‐cell lymphoma treated with anti‐CD19 CAR‐T cells: CARTHYM, a study from the French national DESCAR‐T registry
Jean Galtier, Charles Mesguich, P. Sesques, Vivien Dupont +23 more
2025HemaSphere17 citations Open access
Semantic Scholar
Preliminary Results of Nathali-01: A First-in-Human Phase I/IIa Study of UCART20x22, a Dual Allogeneic CAR-T Cell Product Targeting CD20 and CD22, in Relapsed or Refractory (R/R) Non-Hodgkin Lymphoma (NHL)
J. Abramson, A. Ramakrishnan, A. Piérola, I. Braunschweig +15 more
2023Blood17 citations Open access
Semantic Scholar
TRANSCEND FL: PHASE 2 STUDY RESULTS OF LISOCABTAGENE MARALEUCEL (LISO‐CEL) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)
F. Morschhauser, S. Dahiya, M. Palomba, A. García-Sancho +23 more
2023Hematological Oncology17 citations Open access
Semantic Scholar
Glofitamab Monotherapy in Patients with Non-Hodgkin B-Cell Lymphoma after Failing CAR T-Cell Infusion: Primary Analysis of the Bicar Study, a Phase II Lysa Study
P. Sesques, R. Houot, Y. Al Tabaa, F. Le Bras +18 more
2023Blood15 citations Open access
Semantic Scholar
Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Transcend FL 2-Year Follow-up
L. Nastoupil, Saurabh Dahiya, M. Palomba, A. Martin Garcia-Sancho +26 more
2024Blood14 citations
Semantic Scholar
Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low–Tumor Burden Follicular Lymphoma: Results of a LYSA Study
G. Cartron, E. Bachy, H. Tilly, N. Daguindau +27 more
2023Journal of Clinical Oncology14 citations Open access
Semantic Scholar
Real World Data of Axicabtagene Ciloleucel As Second Line Therapy for Patients with Large B Cell Lymphoma: First Results of a Lysa Study from the French Descar-T Registry
G. Brisou, G. Cartron, E. Bachy, C. Thieblemont +22 more
2023Blood14 citations Open access
Semantic Scholar
EZH2 targeting induces CD38 upregulation and response to anti-CD38 immunotherapies in multiple myeloma
D. Chemlal, E. Varlet, Amélie Machura, Sara Ovejero +11 more
2023Leukemia13 citations Open access
Semantic Scholar
Glofitamab monotherapy in pts with relapsed/refractory (R/R) large B-cell lymphoma (LBCL): Extended follow-up and landmark analyses from a pivotal phase II study.
L. Falchi, C. Carlo-Stella, F. Morschhauser, M. Hutchings +16 more
2023Journal of Clinical Oncology12 citations Open access
Semantic Scholar
Real-Word Experience of CAR T-Cells in Patients with Relapsed/Refractory Follicular Lymphoma : A Descart Registry Analysis from the Lysa
L. Ysebaert, R. Houot, O. Casasnovas, Choquet Sylvain +11 more
2023Blood12 citations
Semantic Scholar
S201: FINAL 7-YEAR FOLLOW UP AND RETREATMENT SUBSTUDY ANALYSIS OF MURANO: VENETOCLAX-RITUXIMAB (VENR)-TREATED PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL)
A. Kater, R. Harrup, T. Kipps, B. Eichhorst +16 more
2023HemaSphere11 citations Open access
Semantic Scholar
A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trial
A. Michallet, R. Letestu, M. Le Garff-Tavernier, L. Campos +29 more
2023Blood Advances11 citations Open access
Semantic Scholar
Efficacy and Safety of Golcadomide, a Novel Cereblon E3 Ligase Modulator (CELMoD) Agent, Combined with Rituximab in a Phase 1/2 Open-Label Study of Patients with Relapsed/Refractory Non-Hodgkin Lymphoma
J. Chavez, L. Nastoupil, F. Morschhauser, G. Cartron +12 more
2023Blood11 citations
Semantic Scholar
Final results on effectiveness and safety of Ibrutinib in patients with chronic lymphocytic leukemia from the non-interventional FIRE study
C. Dartigeas, A. Quinquenel, L. Ysebaert, M. Dilhuydy +68 more
2024Annals of Hematology10 citations Open access
Semantic Scholar
TRANSCEND FL: Phase 2 Study Primary Analysis of Lisocabtagene Maraleucel as Second-Line Therapy in Patients with High-Risk Relapsed or Refractory Follicular Lymphoma
F. Morschhauser, Saurabh Dahiya, M. Palomba, A. Martin Garcia-Sancho +28 more
2023Blood10 citations Open access
Semantic Scholar
DeSUMOylation of chromatin-bound proteins limits the rapid transcriptional reprogramming induced by daunorubicin in acute myeloid leukemias
Mathias Boulanger, Mays Aqrouq, D. Tempé, C. Kifagi +18 more
2023Nucleic Acids Research10 citations Open access
Semantic Scholar
Ironomycin induces mantle cell lymphoma cell death by targeting iron metabolism addiction
Sara Ovejero, L. Alibert, J. Devin, T. Cañeque +17 more
2025Theranostics9 citations Open access
Semantic Scholar
Dexamethasone is associated with reduced frequency and intensity of cytokine release syndrome compared with alternative corticosteroid regimens as premedication for glofitamab in patients with relapsed/refractory large B-cell lymphoma
L. Falchi, Martin Hutchings, Carmelo Carlo-Stella, Franck Morschhauser +15 more
2024Haematologica9 citations Open access
Semantic Scholar
Direct Cell Death Induced by CD20 Monoclonal Antibodies on B Cell Lymphoma Cells Revealed by New Protocols of Analysis
Michael G. Constantinides, Alexis Fayd'herbe De Maudave, M. Potier-Cartereau, Mauricio Campos-Mora +2 more
2023Cancers9 citations Open access
Semantic Scholar
Dexamethasone is Associated with a Lower Incidence and Severity of Cytokine Release Syndrome Compared with Other Corticosteroid Regimens When Given as Premedication for Glofitamab Monotherapy in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)
L. Falchi, Carmelo Carlo-Stella, F. Morschhauser, M. Dickinson +15 more
2023Blood8 citations Open access
Semantic Scholar
Englumafusp Alfa (CD19-4-1BBL) and Glofitamab Combination in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL): Biomarker Results from a Phase I Dose-Escalation Trial
K. Korfi, Ailsa Christiansen, Zhiwen Jiang, Sabine Wilson +20 more
2023Blood7 citations Open access
Semantic Scholar
Author Correction: Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study
Franck Morschhauser, Saurabh Dahiya, M. Palomba, A. Martin Garcia-Sancho +29 more
2024Nature Medicine6 citations Open access
Semantic Scholar
Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Final Results of the Eradic Trial from the Filo Group
A. Michallet, R. Letestu, M. Legarff, S. Morisset +30 more
2024Blood5 citations
Semantic Scholar
5-y Follow-up of Combination of Ibrutinib, Obinutuzumab and Venetoclax for Patients with Newly Diagnosed Mantle Cell Lymphoma, the Oasis Trial
B. Tessoulin, F. Morschhauser, D. Chiron, K. Bouabdallah +10 more
2024Blood5 citations
Semantic Scholar
Preventive plasmapheresis for rituximab related flare in cryoglobulinemic vasculitis
Léa Fornero, T. Kanouni, J. Tudesq, Camille Pochard +6 more
2023Journal of Translational Autoimmunity5 citations Open access
Semantic Scholar
Prospective evaluation of lymphoma response to immunomodulatory therapy criteria in GATA trial from the LYSA group
Y. Al Tabaa, O. Casasnovas, C. Baillet, E. Bachy +15 more
2023Blood Advances5 citations Open access
Semantic Scholar
Measurable residual disease-guided combination of ibrutinib plus venetoclax versus FCR in previously untreated patients with intermediate-risk chronic lymphocytic leukaemia: a phase 2, randomised trial (ERADIC) from the FILO group
A. Quinquenel, R. Letestu, M. Le Garff-Tavernier, Stéphane Morisset +38 more
2025EClinicalMedicine4 citations Open access
Semantic Scholar
Phase IB Study of Oral Selinexor in Combination with Rituximab and Platinum Chemotherapy in Patients with Relapsed/Refractory B-Cell Lymphoma—Final Analysis
M. Maerevoet, O. Casasnovas, G. Cartron, F. Morschhauser +6 more
2024Cancers4 citations Open access
Semantic Scholar
Tazemetostat in Combination with R-CHOP in Patients with High-Risk, Frontline Follicular Lymphoma (Epi-RCHOP): A Phase II Study from the Lysa
L. Ysebaert, F. Lemonnier, G. Brisou, O. Casasnovas +19 more
2023Blood4 citations Open access
Semantic Scholar
Atezolizumab, obinutuzumab and venetoclax for the treatment of patients with relapsed/refractory B non‐Hodgkin lymphoma: Final analysis of a phase II trial from the LYSA group
C. Herbaux, E. Bachy, R. Bouabdallah, S. Guidez +18 more
2025British Journal of Haematology3 citations Open access
Semantic Scholar
IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma
A. Stathis, M. Pirosa, L. Orsucci, P. Feugier +43 more
2024Haematologica3 citations Open access
Semantic Scholar
Outcomes of Primary Mediastinal B-Cell Lymphoma Patients Treated with a PET-Guided Strategy in the Randomized Phase 3 Gained Study Conducted By Lysa
V. Camus, T. Molina, Fabienne Desmots-Loyer, Amine Moslemi +33 more
2024Blood2 citations
Semantic Scholar
Efficacy of a short sandwich protocol, methotrexate, gemcitabine, L‐asparaginase and dexamethasone chemotherapy combined with radiotherapy, in localised newly diagnosed NK/T‐cell lymphoma: A French retrospective study
S. Chaubard, A. Marouf, D. Lavergne, F. Lemonnier +21 more
2023British Journal of Haematology2 citations Open access
Semantic Scholar
POSTER: IBCL-098 TRANSCEND FL: Phase II Study Results of Lisocabtagene Maraleucel (Liso-Cel) in Patients With R/R Follicular Lymphoma (FL)
L. Nastoupil, S. Dahiya, M. Palomba, A. García-Sancho +23 more
2023Clinical Lymphoma, Myeloma & Leukemia2 citations Open access
Semantic Scholar
S233: AXICABTAGENE CILOLEUCEL AS SECOND-LINE THERAPY FOR LARGE B-CELL LYMPHOMA IN TRANSPLANT-INELIGIBLE PATIENTS: FINAL ANALYSIS OF ALYCANTE, A PHASE 2 LYSA STUDY
R. Houot, E. Bachy, G. Cartron, F. Gros +22 more
2023HemaSphere2 citations Open access
Semantic Scholar
Combining PET/CT and Ctdna Assessments at 6 Months from Induction Treatment Better Predicts Outcome in Previously Untreated Patients with Follicular Lymphoma: A Relevance Ancillary Lysa Study
A. Claudel, A. Cottereau, E. Bachy, P. Feugier +23 more
2023Blood2 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

F. Morschhauser×24
Invite
F. Morschhauser — researcher profile on SciRah
E. Bachy×21
Invite
E. Bachy — researcher profile on SciRah
R. Houot×18
Invite
R. Houot — researcher profile on SciRah
C. Thieblemont×14
Invite
C. Thieblemont — researcher profile on SciRah

H. Ghesquières

×11

Invite

H. Ghesquières — researcher profile on SciRah

T. Gastinne×11

Invite

T. Gastinne — researcher profile on SciRah

S. le Gouill×11

Invite

S. le Gouill — researcher profile on SciRah

O. Casasnovas×10

Invite

O. Casasnovas — researcher profile on SciRah

Invite

S. Guidez — researcher profile on SciRah

L. Fornecker×9

Invite

L. Fornecker — researcher profile on SciRah

Invite

P. Feugier — researcher profile on SciRah

Franck Morschhauser×7

Invite

Franck Morschhauser — researcher profile on SciRah